New Targeted Therapies and Small-Cell Lung Cancer

Abstract Small-cell lung cancer (SCLC) accounts for almost 15% of lung carcinomas. Chemotherapy is the cornerstone of treatment of patients with SCLC. In limited disease, median survival is about 12-20 months, with no more than 6%-12% of patients surviving beyond 5 years. In extensive disease, media...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lung cancer 2008-09, Vol.9 (5), p.271-279
Hauptverfasser:	Rossi, Antonio, Maione, Paolo, Palazzolo, Giovanni, Sacco, Paola Claudia, Ferrara, Marianna Luciana, Falanga, Marzia, Gridelli, Cesare
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Bevacizumab Biologic agents Cancer Vaccines - therapeutic use Enzyme Inhibitors - therapeutic use Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Pulmonary/Respiratory Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - pathology Thalidomide Vandetanib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!